Diagnostic and Therapeutic Intervention for Epidermal Growth Factor
Receptor Tyrosine Kinase Inhibitors-associated Cardiotoxicity in
Non-small-cell Lung Cancer: A Case Study
Introduction: Epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKI) are the first-line standard of care for patients
with advanced non-small-cell lung cancer (NSCLC) harboring EGFR
mutations. Rates of serious adverse events are lower with EGFR-TKIs than
other drugs. However, some reports have described EGFR-TKI-associated
cardiac dysfunction, but the underlying mechanism is currently unclear.
Case: A 72-year-old women presented with non-sustained ventricular
tachycardia (NSVT) associated with EGFR-TKI. Because the voltage map
detected a low voltage area in the right ventricle, ablation was
performed. Conclusion: In this patient, NSVT resolved after ablation,
and EGFR-TKI could then be readministered at the original dose.